Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
go back to main search page
Accession:CHEBI:63721 term browser browse the term
Definition:An EC 2.1.2.* (hydroxymethyl-, formyl- and related transferases) inhibitor that interferes with the action of phosphoribosylglycinamide formyltransferase (EC 2.1.2.2).
Synonyms:related_synonym: 10-formyltetrahydrofolate:5'-phosphoribosylglycinamide N-formyltransferase inhibitors;   2-amino-N-ribosylacetamide 5'-phosphate transformylase inhibitor;   5,10-methenyltetrahydrofolate:2-amino-N-ribosylacetamide ribonucleotide transformylase inhibitor;   5,10-methenyltetrahydrofolate:2-amino-N-ribosylacetamide ribonucleotide transformylase inhibitors;   EC 2.1.2.2 inhibitor;   EC 2.1.2.2 inhibitors;   GAR TFase inhibitor;   GAR TFase inhibitors;   GAR formyltransferase inhibitor;   GAR formyltransferase inhibitors;   GAR transformylase inhibitor;   GAR transformylase inhibitors;   glycinamide ribonucleotide formyltransferase inhibitor;   glycinamide ribonucleotide formyltransferase inhibitors;   glycinamide ribonucleotide transformylase inhibitor;   glycinamide ribonucleotide transformylase inhibitors;   phosphoribosylglycinamide formyltransferase (EC 2.1.2.2) inhibitors;   phosphoribosylglycinamide formyltransferase inhibitor;   phosphoribosylglycinamide formyltransferase inhibitors
 xref: Wikipedia:Phosphoribosylglycinamide_formyltransferase



show annotations for term's descendants           Sort by:
pemetrexed term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCC11 ATP binding cassette subfamily C member 11 decreases response to substance
affects response to substance
EXP ABCC11 mRNA results in decreased susceptibility to Pemetrexed; ABCC11 protein results in decreased susceptibility to Pemetrexed
ABCC11 gene SNP affects the susceptibility to Pemetrexed
CTD PMID:20718756 NCBI chr16:48,164,819...48,247,539
Ensembl chr16:48,165,773...48,247,568
JBrowse link
G ABCC5 ATP binding cassette subfamily C member 5 decreases response to substance EXP ABCC5 protein results in decreased susceptibility to Pemetrexed CTD PMID:15897250 NCBI chr 3:183,919,934...184,017,884
Ensembl chr 3:183,919,934...184,017,939
JBrowse link
G ALK ALK receptor tyrosine kinase affects response to substance EXP ALK gene mutant form affects the susceptibility to Pemetrexed CTD PMID:21336183 NCBI chr 2:29,192,774...29,921,586
Ensembl chr 2:29,192,774...29,921,586
JBrowse link
G BBC3 BCL2 binding component 3 increases expression
multiple interactions
EXP Pemetrexed results in increased expression of BBC3 protein
xanthohumol promotes the reaction [Pemetrexed results in increased expression of BBC3 protein]
CTD PMID:35259468 NCBI chr19:47,220,824...47,232,860
Ensembl chr19:47,220,822...47,232,766
JBrowse link
G BCL2 BCL2 apoptosis regulator multiple interactions EXP [Cisplatin co-treated with Pemetrexed co-treated with Valproic Acid] results in decreased expression of BCL2 protein; [Cisplatin co-treated with Pemetrexed co-treated with vorinostat] results in decreased expression of BCL2 protein CTD PMID:19351772 NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
JBrowse link
G BID BH3 interacting domain death agonist multiple interactions EXP [Cisplatin co-treated with Pemetrexed] results in increased cleavage of BID protein CTD PMID:19351772 NCBI chr22:17,734,138...17,774,665
Ensembl chr22:17,734,138...17,774,770
JBrowse link
G C3 complement C3 multiple interactions EXP [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of C3 mRNA; [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of C3 protein CTD PMID:22975265 NCBI chr19:6,677,704...6,720,650
Ensembl chr19:6,677,704...6,730,562
JBrowse link
G CCL2 C-C motif chemokine ligand 2 multiple interactions EXP [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of CCL2 mRNA CTD PMID:22975265 NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208
JBrowse link
G CCND1 cyclin D1 multiple interactions EXP [Cisplatin co-treated with Pemetrexed co-treated with Valproic Acid] results in decreased expression of CCND1 protein; [Cisplatin co-treated with Pemetrexed co-treated with vorinostat] results in decreased expression of CCND1 protein CTD PMID:19351772 NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
JBrowse link
G CDKN1A cyclin dependent kinase inhibitor 1A multiple interactions EXP [Cisplatin co-treated with Pemetrexed co-treated with Valproic Acid] results in increased expression of CDKN1A protein; [Cisplatin co-treated with Pemetrexed co-treated with vorinostat] results in increased expression of CDKN1A protein; [Cisplatin co-treated with Pemetrexed] results in increased expression of CDKN1A protein CTD PMID:19351772 NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,397
JBrowse link
G CFLAR CASP8 and FADD like apoptosis regulator decreases response to substance EXP CFLAR results in decreased susceptibility to Pemetrexed CTD PMID:21726997 NCBI chr 2:201,116,164...201,176,687
Ensembl chr 2:201,116,154...201,176,687
JBrowse link
G CXCL8 C-X-C motif chemokine ligand 8 multiple interactions EXP [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of CXCL8 mRNA; [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of CXCL8 protein CTD PMID:22975265 NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716
JBrowse link
G DDIT3 DNA damage inducible transcript 3 multiple interactions EXP DDIT3 mutant form inhibits the reaction [Pemetrexed results in increased expression of TNFRSF10B] CTD PMID:21726997 NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
JBrowse link
G DHFR dihydrofolate reductase multiple interactions EXP [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of DHFR mRNA CTD PMID:22975265 NCBI chr 5:80,626,226...80,654,983
Ensembl chr 5:80,626,226...80,654,983
JBrowse link
G ERCC1 ERCC excision repair 1, endonuclease non-catalytic subunit multiple interactions
decreases expression
EXP Pemetrexed inhibits the reaction [resveratrol results in increased stability of and results in increased expression of ERCC1 mRNA]; Pemetrexed inhibits the reaction [resveratrol results in increased stability of and results in increased expression of ERCC1 protein]
Pemetrexed results in decreased expression of ERCC1 mRNA; Pemetrexed results in decreased expression of ERCC1 protein
CTD PMID:23912706 NCBI chr19:45,407,334...45,451,547
Ensembl chr19:45,407,334...45,478,828
JBrowse link
G FAS Fas cell surface death receptor increases expression
multiple interactions
EXP Pemetrexed results in increased expression of FAS protein
TP53 protein affects the reaction [Pemetrexed results in increased expression of FAS protein]; TYMS protein inhibits the reaction [Pemetrexed results in increased expression of FAS protein]
CTD PMID:15161716 NCBI chr10:88,964,050...89,017,059
Ensembl chr10:88,953,813...89,029,605
JBrowse link
G FPGS folylpolyglutamate synthase increases response to substance EXP FPGS protein results in increased susceptibility to Pemetrexed CTD PMID:17575230 NCBI chr 9:127,802,858...127,814,506
Ensembl chr 9:127,794,597...127,814,494
JBrowse link
G GGH gamma-glutamyl hydrolase affects response to substance EXP GGH protein affects the susceptibility to Pemetrexed CTD PMID:17575230 NCBI chr 8:63,015,079...63,038,806
Ensembl chr 8:63,014,881...63,039,407
JBrowse link
G IFI30 IFI30 lysosomal thiol reductase multiple interactions EXP [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IFI30 mRNA CTD PMID:22975265 NCBI chr19:18,173,813...18,178,117
Ensembl chr19:18,173,162...18,178,117
JBrowse link
G IL11 interleukin 11 multiple interactions EXP [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL11 mRNA CTD PMID:22975265 NCBI chr19:55,364,382...55,370,463
Ensembl chr19:55,364,382...55,370,463
JBrowse link
G IL13RA2 interleukin 13 receptor subunit alpha 2 multiple interactions EXP [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL13RA2 mRNA CTD PMID:22975265 NCBI chr  X:115,003,982...115,017,616
Ensembl chr  X:115,003,975...115,019,977
JBrowse link
G IL1A interleukin 1 alpha multiple interactions EXP [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL1A mRNA CTD PMID:22975265 NCBI chr 2:112,773,925...112,784,493
Ensembl chr 2:112,773,925...112,784,493
JBrowse link
G IL1RL1 interleukin 1 receptor like 1 multiple interactions EXP [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL1RL1 mRNA CTD PMID:22975265 NCBI chr 2:102,311,563...102,352,356
Ensembl chr 2:102,311,502...102,352,037
JBrowse link
G IL32 interleukin 32 multiple interactions EXP [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL32 mRNA CTD PMID:22975265 NCBI chr16:3,065,403...3,069,530
Ensembl chr16:3,065,297...3,082,192
JBrowse link
G IL33 interleukin 33 multiple interactions EXP [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL33 mRNA CTD PMID:22975265 NCBI chr 9:6,215,149...6,257,983
Ensembl chr 9:6,215,786...6,257,983
JBrowse link
G IL7R interleukin 7 receptor multiple interactions EXP [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL7R mRNA CTD PMID:22975265 NCBI chr 5:35,856,891...35,879,603
Ensembl chr 5:35,852,695...35,879,603
JBrowse link
G KLRC1 killer cell lectin like receptor C1 multiple interactions EXP [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of KLRC1 mRNA CTD PMID:22975265 NCBI chr12:10,442,264...10,454,685
Ensembl chr12:10,442,264...10,454,685
JBrowse link
G KRAS KRAS proto-oncogene, GTPase decreases expression
increases response to substance
EXP Pemetrexed results in decreased expression of KRAS mRNA; Pemetrexed results in decreased expression of KRAS mRNA mutant form; Pemetrexed results in decreased expression of KRAS protein
KRAS gene mutant form results in increased susceptibility to Pemetrexed
CTD PMID:24688052 NCBI chr12:25,205,246...25,250,929
Ensembl chr12:25,205,246...25,250,936
JBrowse link
G MTHFD2 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase increases response to substance EXP MTHFD2 protein results in increased susceptibility to Pemetrexed CTD PMID:24688052 NCBI chr 2:74,198,615...74,217,565
Ensembl chr 2:74,186,172...74,217,565
JBrowse link
G NPM1 nucleophosmin 1 decreases response to substance EXP NPM1 protein results in decreased susceptibility to Pemetrexed CTD PMID:24736981 NCBI chr 5:171,387,116...171,410,900
Ensembl chr 5:171,387,116...171,411,810
JBrowse link
G NRAS NRAS proto-oncogene, GTPase increases response to substance EXP NRAS gene mutant form results in increased susceptibility to Pemetrexed CTD PMID:24688052 NCBI chr 1:114,704,469...114,716,771
Ensembl chr 1:114,704,469...114,716,771
JBrowse link
G RBM17 RNA binding motif protein 17 decreases response to substance EXP RBM17 protein results in decreased susceptibility to Pemetrexed CTD PMID:16061639 NCBI chr10:6,089,034...6,117,447
Ensembl chr10:6,089,034...6,117,457
JBrowse link
G SLC19A1 solute carrier family 19 member 1 multiple interactions
increases response to substance
EXP Pemetrexed inhibits the reaction [SLC19A1 protein results in increased transport of Methotrexate]
SLC19A1 exon mutant form results in increased susceptibility to Pemetrexed
CTD PMID:16505119 PMID:21879757 NCBI chr21:45,502,517...45,563,025
Ensembl chr21:45,493,572...45,573,365
JBrowse link
G SLC46A1 solute carrier family 46 member 1 multiple interactions
increases response to substance
increases activity
EXP Pemetrexed inhibits the reaction [SLC46A1 protein results in increased uptake of Methotrexate]
SLC46A1 protein results in increased susceptibility to Pemetrexed
Pemetrexed results in increased activity of SLC46A1 protein
CTD PMID:21879757 NCBI chr17:28,394,642...28,406,592
Ensembl chr17:28,394,642...28,407,197
JBrowse link
G TNFAIP3 TNF alpha induced protein 3 multiple interactions EXP [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of TNFAIP3 mRNA CTD PMID:22975265 NCBI chr 6:137,866,349...137,883,312
Ensembl chr 6:137,867,214...137,883,314
JBrowse link
G TNFRSF10B TNF receptor superfamily member 10b multiple interactions
increases expression
EXP DDIT3 mutant form inhibits the reaction [Pemetrexed results in increased expression of TNFRSF10B] CTD PMID:21726997 NCBI chr 8:23,020,133...23,069,031
Ensembl chr 8:23,020,133...23,069,031
JBrowse link
G TNFRSF9 TNF receptor superfamily member 9 multiple interactions EXP [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of TNFRSF9 mRNA CTD PMID:22975265 NCBI chr 1:7,915,871...7,940,839
Ensembl chr 1:7,915,871...7,943,165
JBrowse link
G TP53 tumor protein p53 multiple interactions
affects response to substance
EXP TP53 protein affects the reaction [Pemetrexed results in increased expression of FAS protein]
TP53 protein affects the susceptibility to Pemetrexed
CTD PMID:15161716 PMID:17339891 NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,546
JBrowse link
G TRAF1 TNF receptor associated factor 1 multiple interactions EXP [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of TRAF1 mRNA CTD PMID:22975265 NCBI chr 9:120,902,393...120,929,171
Ensembl chr 9:120,902,393...120,929,173
JBrowse link
G TYMP thymidine phosphorylase increases response to substance EXP TYMP protein results in increased susceptibility to Pemetrexed CTD PMID:17575230 NCBI chr22:50,525,752...50,530,085
Ensembl chr22:50,525,752...50,530,032
JBrowse link
G TYMS thymidylate synthetase decreases activity
affects response to substance
multiple interactions
EXP Pemetrexed results in decreased activity of TYMS protein
TYMS affects the susceptibility to Pemetrexed; TYMS protein affects the susceptibility to Pemetrexed
TYMS protein inhibits the reaction [Pemetrexed results in increased expression of FAS protein]
CTD PMID:15161716 PMID:17339891 PMID:21742432 NCBI chr18:657,653...673,578
Ensembl chr18:657,653...673,578
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 26491
    role 26312
      biological role 26291
        biochemical role 25500
          enzyme inhibitor 22385
            EC 2.* (transferase) inhibitor 16116
              EC 2.1.* (C1-transferase) inhibitor 3733
                EC 2.1.2.* (hydroxymethyl-, formyl- and related transferases) inhibitor 3284
                  EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor 41
                    pemetrexed 41
                    pemetrexed disodium + 0
                    pemetrexed disodium heptahydrate 0
paths to the root